ABUS Arbutus Biopharma Quick Ratio

Official company branding of Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma (ABUS) is a biopharmaceutical player developing hepatitis B therapies and possessing valuable LNP technologies. This daily price action reflects a quick ratio of 79.80. Patents for drug delivery methods ensure a high barrier to entry. However, the company's capital is under pressure due to mRNA litigation and uncertainty regarding the outcome of current clinical trials.

ABUS: Arbutus Intermediate Coverage Ratio 07/04/2022 - 10/29/2026

Summary analytical data breakdowns for arbutusbio.com (ABUS)

- market value and analyst target forecast:
Price Chart Arbutus|ABUS - Consensus Target
- market capitalization data:
Market Capitalization Arbutus|ABUS - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value per Share Arbutus Biopharma|ABUS - Accounting Value of Company|Market Value to Book Value Ratio arbutusbio.com|ABUS - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Capital Arbutus Biopharma|ABUS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Arbutus Biopharma Corporation|ABUS - Company Debts|Debts to Book Capitalization Arbutus|ABUS - Long-Term Debt|Company Short-Term Debt Arbutus Biopharma|Quick Ratio arbutusbio.com
- earnings and valuation multiples information:
ABUS - Net Profit
Fundamental valuation:Arbutus - ABUS
Flagship merchandise of Arbutus Biopharma Corp

The long-term sustainability of Arbutus Biopharma (ABUS) depends on its ability to cover short-term liabilities excluding slow-moving inventories, which is reflected in the quick ratio through the sum of cash and accounts receivable. High values for this metric guarantee the financial autonomy necessary to implement costly clinical trials for antiviral programs and to enter into strategic alliances with global pharmaceutical behemoths.

Analysis of competing companies

Arrowhead Pharmaceuticals Inc (ARWR) - Quick Liquidity|Quick Liquidity Indicator Mirum Pharmaceuticals Inc|DVAX (Dynavax Technologies Corp) - Quick Ratio|Quick Ratio inventivapharma.com|Quick Liquidity Indicator GYRE (Gyre Therapeutics)|ASMB (Assembly Bio) - Intermediate Coverage Ratio|Quick Liquidity Galectin Therapeutics Inc. GALT|Genfit SA - Quick Liquidity|DURECT Corp. - Quick Ratio|Interim Coverage Ratio Aligos Therapeutics ALGS|BIVI (biovieinc.com) - Quick Liquidity Indicator|GLMD (Galmed Pharmaceuticals Ltd.) - Quick Liquidity|NDRA (ENDRA) - Quick Ratio|Immediate Liquidity Hepion Pharma HEPA